Add to Favorites Newsroom RSS Share
New York, NY USA

Our News on Newswise

Limited Conclusions Can be Drawn from Study on Limiting Antithrombotic Therapy Beyond One Year for Stent Patients with Atrial Fibrillation

The first randomized trial of its kind was unable to establish non-inferiority of oral anticoagulation (OAC) alone to combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation (AF) and stable coronary artery disease...
24-Sep-2018 5:00 PM EDT Add to Favorites

NIRS-IVUS Detects Patients and Plaques Vulnerable to Subsequent Adverse Coronary Events

Results from the Lipid-Rich Plaque (LRP) study demonstrate the correlation between the presence of non-flow-limiting, non-intervened upon, lipid-rich plaques detected by NIRS-IVUS imaging and the development of a major adverse cardiac event (MACE)...
24-Sep-2018 4:55 PM EDT Add to Favorites

Multicenter Study Finds IVUS-Guided Drug-Eluting Stent Implantation Improves Clinical Outcomes in All-Comer Patients

The first study designed to determine the benefits of intravascular ultrasound (IVUS) guidance over angiography guidance during drug-eluting stent (DES) implantation in all-comer patients found that IVUS improved clinical outcomes by lowering the...
24-Sep-2018 4:55 PM EDT Add to Favorites

Aria CV Wins TCT 2018 Shark Tank Competition

The Cardiovascular Research Foundation (CRF) is pleased to announce that Aria CV has won the TCT 2018 Shark Tank Competition which took place during the Transcatheter Cardiovascular Therapeutics (TCT) 2018, the world’s premier educational meeting...
24-Sep-2018 1:05 PM EDT Add to Favorites

Transcatheter Device Used to Treat Secondary Mitral Valve Regurgitation in Heart Failure Patients Reduces Hospitalizations, Enhances Quality of Life, and Improves Survival

Data presented today from the randomized COAPT trial, which have the potential to significantly change current clinical practice, found that patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite...
23-Sep-2018 3:05 PM EDT Add to Favorites

Study Finds Similar Outcomes with Two Different Valve Types as well as Similar Outcomes with Anesthesia Types during Transcatheter Aortic Valve Replacement

The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (TAVR) in patients with intermediate to high surgical risk found local anesthesia to be both safe and effective. In addition, the...
23-Sep-2018 3:05 PM EDT Add to Favorites

Novel Drug-Eluting Stent with Improved Radiographic Visibility Found to Be Safe and Effective

This first randomized clinical study of a polymer-coated zotarolimus-eluting stent (Resolute Onyx) that utilizes a novel thin-strutted metallic platform allowing for better x-ray visibility was shown to be non-inferior to an ultrathin-strutted...
22-Sep-2018 6:05 PM EDT Add to Favorites

Novel Polymer-Free Amphilimus-Eluting Stent is Noninferior to Durable Polymer Zotarolimus-Eluting Stent

The first large, randomized trial comparing a novel polymer-free amphilimus-eluting stent to the latest-generation permanent polymer drug-eluting stent found that the polymer-free stent was clinically safe and effective.
22-Sep-2018 6:05 PM EDT Add to Favorites


see all news

Our Experts on Newswise

CRF to Hold Free Seminar on Living with Heart Failure for Patients and Caregivers

CRF will hold a free seminar, “Broken Hearts: Living with Heart Failure,” on Tuesday, June 6, 2017 for heart failure patients and caregivers at NewYork-Presbyterian Hospital. The seminar will focus on providing both patients and caregivers a...
9-May-2017 12:05 PM EDT

see all experts

Our YouTube Videos

Youtube feed not yet configured. Is this your Newswise member page? Contact member@newswise.com to configure this module.

About

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.

CRF works to identify, develop and promote the latest advancements in the treatment of heart and vascular disease. By covering all aspects of the research continuum, we’re able to accelerate the speed with which breakthrough therapies reach patients through doctors, improving survival rates and quality of life for patients worldwide.

CRF carries out its mission by pursuing three basic goals:

Innovate
The CRF Skirball Center for Innovation guides early ideas and innovations through comprehensive preclinical research programs to introduce practical clinical therapies to patients.

Investigate
The CRF Clinical Trials Center plans and executes clinical investigations from first-in-man studies to large, multicenter, international trials and provides expert, independent qualitative and quantitative analyses of clinical and imaging data.

Educate
The CRF Center for Education trains practitioners in advanced techniques and innovations at more than 50 educational meetings and conferences each year, including the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

CRF is a 501(c)3 nonprofit organization.

Contacts

Irma Damhuis
Director, External Relations

646-434-4690

Judy Romero
Senior Manager, External Relations

646-434-4608

David Harrison
Harrison Communications

410-804-1728

Twitter

Chat now!